Publikationer Angelica Loskog

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer:

  1. Wenthe J, Naseri S, Hellström A-C, Jernberg Wiklund H, Eriksson E, Loskog A. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Ther. 2020. E-publicerad 1 May.
     
  2. Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A. IL-6 signaling blockade during CD40-mediated immune activation favors anti-tumor factors by reducing TGF-beta, collagen type I and PD-L1/PD1. J Immunol. 2019. 202:787-798.
     
  3. Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini R-M, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. A Phase I/IIa trial using CD19-targeted third generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018. 24:6185-6194.
     
  4. Ireaneus S, Schiza A, Mangsbo S, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ. Local radiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget. 2017. 8:78573-78587.
     
  5. Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017. 23:5846-5857.
     
  6. Schiza A, Wenthe J, Mangsbo S, Eriksson E, Nilsson A, Tötterman TH, Loskog A, Ullenhag G. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients. J Transl Med. 2017, 15:79.
     
  7. Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich L, Christiansson L, Karlsson H, Ullenhag G, Mangsbo S, Dimberg A, Alemany R, Loskog A. Activation of myeloid- and endothelial cells by CD40L immunotherapy supports T-cell expansion and migration into the tumor microenvironment. Gene Therapy. 2017, 24:92-103.
     
  8. Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., Ullenhag, G. Gemcitabine reduces MDSCs, Tregs and TGFb-1 while restoring the Teff:Treg ratio in patients with pancreatic cancer. J Transl Med. 2016, 14:282.
     
  9. Loskog, A., Maleka, A., Mangsbo, S., Svensson, E., Lundberg, C., Nilsson, A., Krause, J., Agnarsdóttir, M., Sundin, A., Ahlström, H., Tötterman, T.H., Ullenhag, G. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016, 114:872-880.
     
  10. Karlsson, H., Svensson, E., Gigg, C., Jarvius, M., Ohlsson Stromberg, U., Savoldo, B., Dotti, G., Loskog, A. Evaluation of intracellular signaling downstream chimeric antigen receptors. Plos One. 2015, 10:e0144787.